Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Eisai Ltd ADR (OP:ESALY)

N/A UNCHANGED

Last Price Updated: 3:59 PM EST, Jan 30, 2023 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	-
Bid (Size)	N/A (0)
Ask (Size)	N/A (0)
Prev. Close	61.51
Today's Range	N/A - N/A
52wk Range	N/A - N/A
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Biogen/Eisai's Popular Alzheimer's Drug Leqembi Is Seeing Slow Adoption - Here's Why ↗

April 24, 2024

Discover the challenges facing Leqembi, the first Alzheimer's drug shown to slow progression. Skepticism among doctors and concerns about efficacy and costs hinder widespread adoption despite FDA...

Via Benzinga

European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer's Drug Lecanemab ↗

March 22, 2024

Biogen and Eisai face delays as EMA postpones the oral explanation for the lecanemab review. Procedural issues at EMA prompt setback, impacting drug evaluation process amid recent EU court ruling.

Via Benzinga

Performance

More News

Eli Lilly's Donanemab For Alzheimer's Hits FDA Speed Breaker, Biogen Stock Gains On Delayed Decision ↗

March 08, 2024

Via Benzinga

Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analyst Says ↗

February 14, 2024

Via Benzinga

Why Is Biogen Stock Trading Lower On Tuesday? ↗

February 13, 2024

Via Benzinga

Evolving Landscape For Alzheimer's Blood Tests Gains Momentum Amid Inaccuracy Concerns ↗

January 12, 2024

Via Benzinga

Merck, Eisai Report Yet Another Failure For Keytruda Plus Lenvima Combo Trial, This Time In Endometrial Cancer ↗

December 08, 2023

Via Benzinga

Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others ↗

November 21, 2023

Via Benzinga

Biogen Revises Annual Forecast As Reata M&A And Alzheimer's Drug Expenses Hit Bottomline, Stock Slides ↗

November 08, 2023

Via Benzinga

Improved Alzheimer's Diagnosis Access: CMS Expands Amyloid PET Scan Usage ↗

October 13, 2023

Via Benzinga

Is There A Blood Test for Alzheimer's? Progress Underway, But Not Quite Ready ↗

October 11, 2023

Via Benzinga

LuMind CEO At Odds With Neurologists Over Alzheimer's Drugs Made By Biogen, Eli Lilly ↗

October 10, 2023

Via Benzinga

Amazon Invests $4B In ChatGPT Competitor, Hollywood Writers Accept Tentative Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories ↗

September 25, 2023

Via Benzinga

Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi ↗

September 25, 2023

Via Benzinga

Merck-Eisai Partnered Two Keytruda/Lenvima Combo Trials Flunk In Certain Types Of Lung Cancer ↗

September 22, 2023

Via Benzinga

Merck/Eisai's Cancer Combo Therapy Ambition Dashed Once Again, Companies Throw Towel On Head & Neck Trial ↗

August 25, 2023

Via Benzinga

Biogen's Just Made Its Biggest Acquisition. Here's What You Need to Know. ↗

August 01, 2023

Via The Motley Fool

Biogen Shares Fall After FDA Approval Of Alzheimer's Drug Leqembi

July 10, 2023

Via MarketBeat

Expanded Medicare Coverage For Biogen-Eisai's Leqembi Signals a Turning Point in Alzheimer's Treatment: Analysts ↗

July 07, 2023

Via Benzinga

Senator Bernie Sanders Puts Brakes on Health Agency Nominees Until Drug Pricing Issue is Addressed ↗

June 14, 2023

Via Benzinga

FTC Sues To Block Microsoft-Activision Blizzard Deal, Netflix's First Sports Streaming Debut, EU Mulls Antitrust Case Against Google's Ad-Tech Business: Today's Top Stories ↗

June 13, 2023

Via Benzinga

Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources ↗

June 13, 2023

Via Benzinga

Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote ↗

June 12, 2023

Via Benzinga

Nasdaq, S&P 500 Futures Signal Strong Start To Week On Hopes Of Fed Pause: Why This Analyst Is Pricing In A 20% Gain From Bear Market Low ↗

June 12, 2023

Via Benzinga

Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable' ↗

June 08, 2023

Via Benzinga

Frequently Asked Questions

Is Eisai Ltd ADR publicly traded?

Yes, Eisai Ltd ADR is publicly traded.

What exchange does Eisai Ltd ADR trade on?

Eisai Ltd ADR trades on the OTC Traded

What is the ticker symbol for Eisai Ltd ADR?

The ticker symbol for Eisai Ltd ADR is ESALY on the OTC Traded

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.